SG&A Expense Trends: AbbVie Inc. vs ImmunityBio, Inc.

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AbbVie Inc. and ImmunityBio, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses.

AbbVie Inc.

From 2014 to 2023, AbbVie Inc. has seen a significant increase in SG&A expenses, peaking in 2022 with a 150% rise compared to 2016. This upward trend reflects AbbVie's aggressive expansion and marketing strategies, crucial for maintaining its market dominance.

ImmunityBio, Inc.

Conversely, ImmunityBio, Inc. has maintained a more conservative approach, with SG&A expenses showing a modest increase of around 30% over the same period. This suggests a focus on cost efficiency and strategic investments.

These trends highlight the diverse financial strategies within the pharmaceutical sector, offering insights into how companies allocate resources to drive growth and innovation.